GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Current Ratio

Sio Gene Therapies (Sio Gene Therapies) Current Ratio : 21.97 (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sio Gene Therapies's current ratio for the quarter that ended in Dec. 2022 was 21.97.

Sio Gene Therapies has a current ratio of 21.97. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Sio Gene Therapies's Current Ratio or its related term are showing as below:

SIOX's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.79
* Ranked among companies with meaningful Current Ratio only.

Sio Gene Therapies Current Ratio Historical Data

The historical data trend for Sio Gene Therapies's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Current Ratio Chart

Sio Gene Therapies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Current Ratio
Get a 7-Day Free Trial 3.40 2.63 2.67 12.20 5.52

Sio Gene Therapies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.95 5.52 6.46 11.12 21.97

Competitive Comparison of Sio Gene Therapies's Current Ratio

For the Biotechnology subindustry, Sio Gene Therapies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sio Gene Therapies's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Current Ratio distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's Current Ratio falls into.



Sio Gene Therapies Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Sio Gene Therapies's Current Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Current Ratio (A: Mar. 2022 )=Total Current Assets (A: Mar. 2022 )/Total Current Liabilities (A: Mar. 2022 )
=71.736/13.002
=5.52

Sio Gene Therapies's Current Ratio for the quarter that ended in Dec. 2022 is calculated as

Current Ratio (Q: Dec. 2022 )=Total Current Assets (Q: Dec. 2022 )/Total Current Liabilities (Q: Dec. 2022 )
=47.272/2.152
=21.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sio Gene Therapies  (OTCPK:SIOX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Sio Gene Therapies Current Ratio Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sio Gene Therapies (Sio Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
130 West 42nd Street, 26th Floor, New York, NY, USA, 10036
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Executives
Parag V Meswani officer: Chief Commercial Officer 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu officer: Chief Executive Officer C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif officer: Principal Financial Officer C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo 10 percent owner C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado 10 percent owner 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901